PF-06454589 is primarily used in the field of pharmaceutical research and development. It is being studied for its potential as a therapeutic agent, particularly in the treatment of neurodegenerative disorders such as Alzheimer's disease. The compound is designed to target specific biochemical pathways involved in the progression of these diseases, aiming to slow down or halt their development. Researchers are focused on evaluating its efficacy, safety, and pharmacokinetics in preclinical and clinical trials. The goal is to determine its suitability for use in humans, with the hope of providing a new treatment option for patients suffering from these debilitating conditions.